1
Department of Biology, College of Science, University of Misan, Amarah 62001, Iraq.
2
Department of Biology, College of Science, University of Basrah, Basrah 61001, Iraq.
10.24271/psr.2026.557015.2436
Abstract
Mannoprotein was extracted and assessed as a promising vaccine against Candida albicans. The crude extract was initially identified by Fourier- transform infrared spectroscopy (FTIR) that established the high level of similarity with the mannoprotein profiles, which suggested preliminary identification. After the primary extraction, a purification was done to increase antigenic specificity. The resulting, purified mannoprotein fraction was then produced as a vaccine and immunized into rats in a control experimental protocol. Immunological measurements revealed a moderate, non-significant elevation in concentration of IgG and inflammatory cytokines, including Th1/Th17- associated mediators, before challenge. In spite of not statistically significant of these changes, the current findings indicate immune activation of humoral and cellular immune response . Anyway, after experimental challenge with viable C. albicans, a clear decline in IgG antibody titer and inflammatory cytokines was observed in the treated groups by comparing to the control group. This reduction may reflect antigen consumption during active infection, reflecting immune engagement and pathogen-neutralizing activity. The post-challenge decrease may also indicate that the vaccine competent to early pathogen clearance, so it can reduce the need for sustained inflammatory signaling pathway. Generally, our study proves that purified mannoprotein controls immunogenic potential, capable of priming an early immune response before infection. These results support further development of mannoprotein-based vaccines as a promising strategy for prophylactic control of candidiasis. Further studies focusing on long-term immune memory and preventative potency across different infection models are recommended to confirm these preliminary results. The absence of an unvaccinated non- infected control group represents a limitation of our study and may affect the interpretation of immune responses.
Abbas,N Fadhil and Shani,W Sadoon. (2026). Vaccination Protocol with Purified Mannoproteins Against Invasive Candidiasis. Passer Journal of Basic and Applied Sciences, 8(2), 1027-1037. doi: 10.24271/psr.2026.557015.2436
MLA
Abbas,N Fadhil, and Shani,W Sadoon. "Vaccination Protocol with Purified Mannoproteins Against Invasive Candidiasis", Passer Journal of Basic and Applied Sciences, 8, 2, 2026, 1027-1037. doi: 10.24271/psr.2026.557015.2436
HARVARD
Abbas N Fadhil, Shani W Sadoon. (2026). 'Vaccination Protocol with Purified Mannoproteins Against Invasive Candidiasis', Passer Journal of Basic and Applied Sciences, 8(2), pp. 1027-1037. doi: 10.24271/psr.2026.557015.2436
CHICAGO
N Fadhil Abbas and W Sadoon Shani, "Vaccination Protocol with Purified Mannoproteins Against Invasive Candidiasis," Passer Journal of Basic and Applied Sciences, 8 2 (2026): 1027-1037, doi: 10.24271/psr.2026.557015.2436
VANCOUVER
Abbas N Fadhil, Shani W Sadoon. Vaccination Protocol with Purified Mannoproteins Against Invasive Candidiasis. PJBAS. 2026;8(2):1027-1037. doi: 10.24271/psr.2026.557015.2436